Status:
COMPLETED
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients
Lead Sponsor:
Peking University First Hospital
Conditions:
Kidney Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Second primary malignancy (SPM) significantly impacts the survival and prognosis of patients. This study endeavors to identify risk and prognostic factors associated with SPM after first primary kidne...
Detailed Description
In recent years, with the advancement of cancer treatment techniques and the prolonged survival of patients, the prevalence of Second primary malignancy (SPM) has been escalating, emerging as a signif...
Eligibility Criteria
Inclusion
- (1) Diagnosed age was between 18 and 80 years old
- (2) Diagnosed histologically confirmed as first primary kidney cancer
- (3) The staging of kidney cancer was early or localized advanced (T1/2/3N0M0)
- (4) Detailed survival data and follow-up information should be provided
Exclusion
- (1) Histological conformation for diagnosis was unavailable
- (2) The type of reporting source was "Death certificate only" or "Autopsy only"
- (3) Patients with other malignancies before the diagnosis of primary kidney cancer
- (4) The staging of kidney cancer was not early or localized advanced (T1/2/3N0M0)
- (5) Diagnosis interval between first primary malignancy (FPM) and second primary malignancy (SPM) was less than 6 months
- (6) The information was not complete
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
72408 Patients enrolled
Trial Details
Trial ID
NCT06531629
Start Date
January 1 2000
End Date
December 31 2020
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034